CeriBell, Inc. (CBLL) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margins ⢠Large operating losses ⢠Strong liquidity CBLL combines a very strong balance sheet and gross margins with persistent large operating losses, negative free cash flow, heavy investment outflows and valuation metrics that reflect asset/optionality rather than current earnings. #strong-balanceâ
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Support tested ⢠Resistance cluster Support Level: $17.50â$17.80 Resistance Level: $20.70â$20.90 CBLL is in a short-term downtrend over the last month, sliding ~7.8% from $19.34 to $17.83 and testing support at $17.5â$17.8, while upside needs a reclaim above $20.7â$20.9 to turn bullish.
Sentiment & News
Key News Insights: ⢠Revenue outperformance ⢠Q4 operating loss ⢠Strong analyst support CeriBell beat revenue estimates despite a Q4 loss, has favorable analyst sentiment and active investor outreach as it repositions within smallâcap medical peers.
AI Summary
Ceribell has shifted from a speculative R&D story to a commercially-scaling, highâmargin device company where the investment thesis now pivots on execution â namely sustaining >20% revenue growth, preserving midâtoâhighâ80s gross margins, and delivering sequential improvement to operating cash flow/opEx leverage (failure to do so or adverse ITC/legal/tariff outcomes would likely force dilution and re-rate downside).
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |